SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals has published its audited standalone and consolidated financial results for Q4 and full year ended March 31, 2026, in newspapers as required by SEBI regulations. The results were approved by the Board on May 22, 2026. For the standalone business, total income was Rs 1,085.73 lakhs in Q4 and Rs 3,906.20 lakhs for the full year. Net profit after tax was Rs 7.50 lakhs for Q4 and Rs 104.96 lakhs for the year. Consolidated total income was Rs 8,952.43 lakhs with net profit after tax of Rs 10,198.91 lakhs. The Board has recommended a final dividend of Rs 1 per equity share for FY 2026, subject to shareholder approval at the AGM.
The company reported modest standalone profitability with EPS of Rs 1.02 for the year. The recommended dividend of Rs 1 per share provides a small income return for shareholders. Consolidated results show significantly higher income, suggesting other business segments or subsidiaries contribute substantially to group performance.